INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
A phase 2/3 trial testing INBRX-106 in head and neck squamous cell carcinoma, active and no longer recruiting.
Overview
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC is a phase 2/3 interventional study registered as NCT06295731, led by Inhibrx Biosciences, and active but no longer recruiting when checked on 2026-09-11. Official title: A Phase 2/3, Randomised Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First Line Treatment for Patients With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing PD-L1 (CPS ≥20) (HexAgon-HN). Planned enrolment is 410 participants (estimated). The study started in 2024-05-14 and primary completion is expected in 2029-05. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialAssessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
Shares Head and neck squamous cell carcinoma and the tag ctgov-ingest.
- TrialA Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Shares Head and neck squamous cell carcinoma and the tag ctgov-ingest.
- TrialStudy of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Shares Head and neck squamous cell carcinoma and the tag ctgov-ingest.
- TrialJNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Shares Head and neck squamous cell carcinoma and the tag ctgov-ingest.
- TrialA Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
Shares Head and neck squamous cell carcinoma and the tag ctgov-ingest.
- TrialA Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN
Shares Head and neck squamous cell carcinoma and the tag ctgov-ingest.
- TrialA Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Shares Head and neck squamous cell carcinoma and the tag ctgov-ingest.
- TreatmentJNJ-90301900
Shares Head and neck squamous cell carcinoma and the tag ctgov-ingest.